RecruitingNot ApplicableNCT06658067

Continuous Glucose Monitors (CGMs) for All: Studying the Impact of Expanding CGM Access

CGMs for All: Studying the Impact of Expanding CGM Access


Sponsor

Yale University

Enrollment

17 participants

Start Date

Nov 12, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

This non-blinded, non-randomized pre-post study will examine the impact of providing CGM sensors free of charge to adult patients of Fair Haven Community Health Care with poorly controlled type 2 diabetes on glycemic control and quality of life.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study examines whether giving free access to continuous glucose monitors (CGMs) — devices that track blood sugar continuously — helps low-income adults with poorly controlled type 2 diabetes manage their blood sugar better. Participants currently cannot afford CGM sensors on their own. **You may be eligible if...** - You have type 2 diabetes with an HbA1c of 8.0% or higher (meaning your blood sugar is not well controlled) - You have been on insulin for at least one year - You cannot currently afford CGM sensors - You are willing to wear a CGM device and work with your doctor on medication adjustments **You may NOT be eligible if...** - You are new to insulin (insulin-naive) - You have had diabetic ketoacidosis in the past 6 months - You have end-stage kidney disease - You have active insurance that covers enough of the CGM cost - You are pregnant Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEContinuous Glucose Monitor (CGM)

The first CGM sensor will be applied as directed during the first visit with a brief training by staff. Participant will be instructed to remove and replace the device every 14 days for the remainder of the 3-month trial period. Participant will also be instructed to scan the sensor three times daily. Compliance may be tracked via remote accessing of the blood glucose log on the online FreeStyle portal. CGM models used will include the Abbott FreeStyle Libre 2 and 3 and Dexcom G5, G6 and G7.


Locations(1)

Fair Haven Community Health Care (FHCHC)

New Haven, Connecticut, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06658067


Related Trials